openPR Logo
Press release

Alzheimer's Disease Therapeutics and Diagnostics Market Overview for 2028

08-11-2022 12:53 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Triton Market Research

Alzheimer's Disease Therapeutics Diagnostics Market

Alzheimer's Disease Therapeutics Diagnostics Market

A recent study by Triton Market Research titled 'Global Alzheimer's Disease Therapeutics and Diagnostics Market,' covers the Global Analysis and Forecasts by Diagnostics (Positron Emission Tomography, Electroencephalography, Lumbar Puncture Test, Blood Test, Computed Tomography, Magnetic Resonance Imaging, Other Diagnostics), by Therapeutics (Drug Type [Marketed Drugs, Pipeline Drugs], Disease Stage [Prodromal Stage, Late Stage: Severe AD, Early/Middle Stage: Mild To Moderate AD], Generic & Branded [Branded, Generic]), and by Regional Outlook (North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa).

Request Free Sample of the Global Alzheimer's Disease Therapeutics and Diagnostics Market Report @ https://www.tritonmarketresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostic-market#request-free-sample

Triton Market Research, in its report, has predicted the global Alzheimer's disease therapeutics and diagnostics market to develop with a CAGR of 6.98% during the forecasting years 2022-2028. It is likely to gain revenue worth $10991.17 million by 2028.

The high prevalence rate of Alzheimer's disease (AD) globally is a key driver for the market and emphasizes the pressing need to develop effective diagnosis and treatment methodologies. Various novel diagnostic technologies have been developed for AD, including the invention that detects mutated proteins in subcellular compartments. However, the failure of drugs in the final stages of clinical trials is anticipated to hamper the studied market's development.

The market for Alzheimer's disease therapeutics and diagnostics is segmented primarily into diagnostics and therapeutics. Based on diagnostics, it is divided into positron emission tomography, electroencephalography, lumbar puncture test, blood test, computed tomography, magnetic resonance imaging, and other diagnostics.

Whereas, based on therapeutics, it is divided broadly into drug type, disease stage, and generic & branded. Drug type is further divided into marketed drugs and pipeline drugs. Whereas, disease stage is further divided into prodromal stage, late stage: severe AD, early/middle stage: mild to moderate AD. Lastly, generic & branded is further classified into branded and generic.

The Asia-Pacific region is expected to showcase the fastest growth in the global market during the considered period. The market in this region is primarily driven by the presence of a vast population, particularly in countries like China and India. Thus, the geriatric population in this region is also high. The presence of an increased patient pool calls for the adoption of diagnosis and treatment methods for Alzheimer's disease.

Baxter International Inc, Teva Pharmaceutical Industries Ltd, Johnson and Johnson, Zydus Cadila, Siemens Healthineers AG, Novartis AG, Pfizer Inc, Biogen Inc, Allergan Plc (acquired by Abbvie), Eli Lilly & Company, Amarantus Bioscience Holdings Inc, Merck and Co, GE Healthcare, Lupin Limited, Sun Pharmaceuticals Industries Ltd, F. Hoffmann-La Roche AG, Cognoptix Inc, and Eisai Co Ltd are the well-known players in the Alzheimer's disease therapeutics and diagnostics market.

Purchase this Report @ https://www.tritonmarketresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostic-market#purchase-option

Question & Answer: Alzheimer's disease therapeutics and diagnostics Market

Question 1: Which is the key driver of the Alzheimer's disease therapeutics and diagnostics market?

Answer: The high prevalence rate of Alzheimer's disease (AD) globally is a key driver for the market and emphasizes the pressing need to develop effective diagnosis and treatment methodologies. Various novel diagnostic technologies have been developed for AD, including the invention that detects mutated proteins in subcellular compartments.

Question 2: What factor is anticipated to hamper the studied market's development?

Answer: The failure of drugs in the final stages of clinical trials is anticipated to hamper the studied market's development.

Question 3: Which region is expected to grow the fastest in the global market during the considered period?

Answer: The Asia-Pacific region is expected to showcase the fastest growth in the global market during the considered period. The market in this region is primarily driven by the presence of a vast population, particularly in countries like China and India. Thus, the geriatric population in this region is also high. The presence of an increased patient pool calls for the adoption of diagnosis and treatment methods for Alzheimer's disease.

Question 4: Which are the well-known players in the Alzheimer's disease therapeutics and diagnostics market?

Answer: Baxter International Inc, Teva Pharmaceutical Industries Ltd, Johnson and Johnson, Zydus Cadila, Siemens Healthineers AG, Novartis AG, Pfizer Inc, Biogen Inc, Allergan Plc (acquired by Abbvie), Eli Lilly & Company, Amarantus Bioscience Holdings Inc, Merck and Co, GE Healthcare, Lupin Limited, Sun Pharmaceuticals Industries Ltd, F. Hoffmann-La Roche AG, Cognoptix Inc, and Eisai Co Ltd are the well-known players in the Alzheimer's disease therapeutics and diagnostics market.

Related Report:

Global Sleep Apnea Therapeutics and Diagnostics Market: https://www.tritonmarketresearch.com/reports/sleep-apnea-therapeutics-and-diagnostics-market

The global sleep apnea therapeutics and diagnostics market is deemed to grow at a CAGR of 6.90% in the estimated duration 2021-2028. In 2020, the market was valued at $4356.9 million, and is anticipated to gain $8243.2 million by 2028.

There are three main types of sleep apnea -central sleep apnea, obstructive sleep apnea, and complex sleep apnea syndrome. The rising incidence of sleep apnea, growing public awareness, supportive government programs & initiatives, and technological advancements are some factors anticipated to drive the growth of the studied market over the forecast period.

On the other hand, countries like India, Mexico, Brazil, and Saudi Arabia do not have government-regulated reimbursement policies in place for sleep apnea devices. The lack of reimbursement for sleep apnea devices in these emerging economies thus restricts the adoption of therapeutic and diagnostic devices.

Triton Market Research
196, wards wharf approach
London E16 2EQ
Phone: +44 7441 911839
Email: sales@tritonmarketresearch.com
Website: https://www.tritonmarketresearch.com/

We are a leading market research company with offices in the UK, providing the best online market research and data search reports to our clients.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer's Disease Therapeutics and Diagnostics Market Overview for 2028 here

News-ID: 2703413 • Views: 298

More Releases from Triton Market Research

The Global X-Ray Tube Market Evaluated to Progress at $3470.77 Million by 2028
A recent study by Triton Market Research titled 'Global X-Ray Tube Market' includes the Global Analysis and Forecasts by Type (Rotating Anode Tube, Stationary X-Ray Tube), Industry Vertical (Manufacturing, Food, Healthcare, Aerospace & Defense, Other Industry Verticals), and by Geography (North America, Asia-Pacific, Europe, Latin America, Middle East and Africa). An x-ray tube is a vacuum tube that helps convert electrical power into x-rays, and is widely used
The Global Video Analytics Market Assessed to Develop at $11121.01 Million by 20 …
A recent study by Triton Market Research titled 'Global Video Analytics Market' entails the Global Analysis and Forecasts by Deployment (On-premises, Cloud), Software Types (Detection Software [Motion Detection Software, Object Detection Software, Other Detection Software], Recognition Software [Facial Recognition Software, License Plate Recognition Software], Crowd Management Software), Application (Commercial, Transport & Logistics, Government, Other Applications), and by Geography (North America, Middle East and Africa, Latin America, Europe, Asia-Pacific). Video
The Global Protective Clothing Market for EMS is Projected to Acquire $4494.57 M …
A recent study by Triton Market Research titled 'Global Protective Clothing Market for Emergency Medical Services' entails the Global Analysis and Forecasts by Type (Disposable, Reusable), Product (Wipes, Gloves, Face Masks and Hats, Protective Eyewear & Cleanroom Goggles, Suits/Coveralls, Footwear & Overshoes, Aprons, Others), and by Geography (Middle East and Africa, Asia-Pacific, North America, Europe, Latin America). Protective clothing refers to apparel or equipment produced to protect
The Global Precision Medicine Market Estimated to Expand at $128.17 Billion by 2 …
A recent study by Triton Market Research titled 'Global Precision Medicine Market' includes the Global Analysis and Forecasts by Application (Neurology/Physiatry, Cardiovascular, Oncology, Gastroenterology, Infectious Diseases, Lifestyle and Endocrinology, Other Applications), Component (Precision Diagnostics [Molecular Diagnostics (Liquid Biopsy, Companion Diagnostics, Non-Invasive Prenatal Testing [NIPT], Other Molecular Diagnostics], Medical Imaging (Imaging Computer-Aided Detection [CADX], Imaging Analytics)], Precision Therapeutics [Drug Discovery and Research, Clinical Trials, Cell Therapy, Gene Therapy], Applied Science [Genomics

All 5 Releases


More Releases for Alzheimer

Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Alzheimer Diagnostic Tests Market GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as